 
 
 
 
 
Title: Ixekizumab in the Treatment of Pi[INVESTIGATOR_901327] (PRP)  
 
Study ID: [REMOVED]  
 
Document Date: February 27 th, 2020  
 

Page 1 of 30  
 
 
 
 
 
An open label pi[INVESTIGATOR_901328] (PRP)  
 
 
 
 
 
 
 
  Protocol Version Number : 4.1 
Protocol Version Date : [ADDRESS_1264197]:  Ixekizumab  
IND/IDE Status:  Exempt  
Principal Investigator  [INVESTIGATOR_312178], MD, PhD  
Department of Dermatology  
Oregon Health & Science University, Center for Health and Healing  
[ADDRESS_1264198], CH16D  
Portland, OR [ZIP_CODE]   
Phone: [PHONE_6529]  
Fax: [PHONE_6530]  
Email: [EMAIL_6142]  
Sponsor:  Oregon Health & Science University  
Funding Source:  Lilly, Inc.  
Trial Configuration  Single center, open label, interventional , investigator -initiated  trial 

Page 2 of 30 CLINICAL PROTOCOL SYNOPSIS  
 
Title An open label pi[INVESTIGATOR_901329] p ilaris (PRP)  
Principal  Investigator  [INVESTIGATOR_312178], MD, PhD  
Objectives  To determine whether ixekizumab provides clinical improvement for 
subject s with PRP who are candidates for systemic therapy  
Trial Configuration  
Main Trial (a)  
Subset Analysis (b)   
(a) Single center, open label, interventional , investigator -initiated  
trial 
(b) Observational  cohort  
Setting  (a) The trial will recruit 15 adults with severe (defined by [CONTACT_901346] ( PASI ) score  > 10 ) PRP through dermatologist 
offices, recruitment letters, and advertisement.  
 
Study visits will occur at Screening , weeks 0, 2, 4, 8, 12, 16, 24, 
and 36. For subjects living > 30 miles from OHSU, only study 
visits at weeks 0 and 24 will be required in -person; the remaining 
visits optionally will be performed via secure video -conferencing 
using the OHSU Nexus (Cisco Meeting) app , between the 
investigator and the subject,  accessed b y the subjects with a 
one-time-use video hyperlink sent from OHSU MyChart  or email , 
as well as a RE DCap survey  sent via email . 
 
(b) The observational cohort will recruit up to 15 adults to include 
patients with a current or historic  diagnosis of PRP who are no t 
interested in or eligible for part (a) . These subjects will complete 
questionnaires and have the opportunity to provide specimens 
for banking and further research (saliva – at OHSU or through 
mailing services; blood and tissue – at OHSU).  
Sample Size Estimate  With measurement of the mean paired difference in PASI score before 
and after treatment of a minimum of [ADDRESS_1264199] 80% 
power at the 0.[ADDRESS_1264200] deviation is 8 -points. Due to the uncertainty 
inherent with a pi[INVESTIGATOR_799], the goal number of subjects with PRP who 
will be recruited for the interventional study is 15.  In addition, the 
observational cohort will recruit up to an additional 15 patients.  
Number of Part icipants  (a) 15 subjects with severe PRP for the interventional trial,  
(b) Up to 15 subjects in  the observational cohort.  
Eligibility Criteria  (a) Inclusion criteria  
• Willingness to comply with study procedures/requirements  
• Capable of giving informed consent  
• Diagnosis of PRP by [CONTACT_312228].  
• Male age 18 -99. 
• Female age 18 -99; either of non -childbearing potential or of 
childbearing potential who test negative for pregnancy and 
agree to use a reliable method of birth control or remain 
Page [ADDRESS_1264201] dose of ixekizumab.  
• PASI score of 10 or greater at baseline  (severe disease) .  
• Are a candidate for phototherapy and/or systemic therapy.  
• Willingness to travel to OHSU for all study visits, or  living > 30 
miles from OHSU and willing/able to participate in remote 
videoconferencing visits with access to a computer with internet 
and webca m capabilities .  
 
Exclusion criteria  
• Known malignancy or lymphoproliferative disease (except 
treated basal cell skin cancer, treated squamous cell skin 
cancer, or treated cervical carcinoma in situ) for at least 5 
years.  
• Active, untreated, acute or chronic  infection  (such as untreated 
tuberculosis) , or immunocompromised to an exten t that such 
that participation in the study would pose an unacceptable risk 
to the subject . (Treated infections such as latent tuberculosis 
after completion of the appropriate the rapy are not excluded.)  
• Positive for human immunodeficiency virus, hepatitis B virus, or 
hepatitis C virus.  
• Previous treatment with any agent that targets interleukin 17 
specifically.  
• Systemic treatment or phototherapy for PRP within the past 4 
weeks or 5  half-lives prior to baseline, whichever is longer. For 
biologic therapi[INVESTIGATOR_014], the specific washout periods used will be: 
etanercept <28 days; infliximab, adalimumab, or alefacept <60 
days; golimumab <90 days; ustekinumab <8 months; rituximab 
or efalizumab <1 2 months.  
• Have a known allergy or hypersensitivity to any biologic 
therapy that w ould pose an unacceptable risk to the subject  if 
participating in this study.  
• Have a live vaccine within [ADDRESS_1264202] a live vaccine during the course of study.  
• Had any major surgery within [ADDRESS_1264203] . 
• Presence of significant uncontrolled cerebrovascular, 
respi[INVESTIGATOR_696], hepatic, renal, gastrointestinal, endocrine, 
hematologic, neurologic, or neuropsychiatric disorders, or 
abnormal laboratory screening values that, in the opi[INVESTIGATOR_1070], pose an unacceptable risk to the subject  if 
participating in the study or of interfering with the interpretation 
of the data.  
• Presence of inflammatory bowel disease  
• Have clinical laboratory test results at screening that are 
outsi de the normal reference range of the population and are 
considered clinically significant, or have any of the following 
specific abnormalities: Neutrophil count <1500 cells/µL, 
lymphocyte count <500 cells/µL, platelet count <100,000 
cells/µL, AST or ALT > 2.5 times the upper limit of norm al, 
hemoglobin <8.5 g/dL for male subject s and <8.0 g/dL for 
Page [ADDRESS_1264204] s, serum creatinine >2.0 mg/dL.  
• Women who are lactating or breastfeeding.  
• Have any other condition that precludes the subject  from 
following and completing the protocol, in the opin ion of the 
investigator.  
• Are investigator site personnel directly affiliated with this study 
and/or their immediate families (spouse, parent, child, or 
sibling).  
• Are currently enrolled in, or discontinued from a clinical trial 
involving an investigational product or non -approved use of a 
drug or device within the last [ADDRESS_1264205] administration of the drug, whichever is 
longer, or concurrently enrolled in any other type of medical 
research judged not to be scient ifically or medically compatible 
with this study.  
Eligibility Criteria (b)  Inclusion criteria  
• Willingness to comply with study procedures/requirements . 
• Capable of giving informed consent . 
• Diagnosis of PRP by [CONTACT_312228]  – may 
currently be in remission or on systemic therapy.  
• Male or Female 18-99. 
 
Exclusion criteria  
• Have any condition that precludes the subject  from following 
and completing the protocol, in the opi[INVESTIGATOR_871].  
• Are investigator site personnel directly affiliated with this study 
and/or their immediate families (spouse, parent, child, or 
sibling).  
• Are currently enrolled in any type of medical research judged 
not to be scientifically or medically compatible with this study.  
Description of Interventions  (a) Subjects with PRP will be treated with ixekizumab for 20 weeks 
using the FDA -approved dosing schedule for psoriasis (160 mg 
subcutaneous injection at week 0 followed by 80 mg 
subcutaneous injection at weeks 2, 4, 6, 8, 10, 12, 16, and 20).  
(b) No intervention  
Duration of Study  (a) The duration of the study will be 36 weeks  
(b) Completed in a single encounter  
Outcome Measures  The primary outcome will be  the mean change from basel ine PASI at 
week -24 after treatment with ixekizumab.  
Secondary and mechanistic outcomes include measurement of 
improvement in body surface area, nail involvement, quality of life, itch, 
pain; time to improvement by 50%; sustained remission at 36 weeks; 
and correlation of improvement with germline genetic mutations and 
cutaneous cytok ine expression.  
Statistical Methods  Mean improvement from baseline PASI at week -24 will be analyzed for 
statistical significance using a paired, two -tailed student’s t -test. 
 
  
Page 5 of 30 Table of Contents  
CLINICAL PROTOCOL SYNOPSIS  ................................ ................................ ................................ ........... 2 
ABBREVIATIONS ................................ ................................ ................................ ................................ .7 
1.  BACKGROUND  ................................ ................................ ................................ ............................... 8 
1.1.  OVERVIEW OF PI[INVESTIGATOR_901330] (PRP)  AND IXEKIZUMAB  ................................ ................................ ... [ADDRESS_1264206] ................................ ................................ ..................  10 
3.2.4. Exploratory/Mechanistic Endpoints  ................................ ................................ ...........................  10 
4.  STUDY ENROLLMENT AND WITHDRAWAL  ................................ ................................ ....................  11 
4.1.  INCLUSION CRITERIA  ................................ ................................ ................................ ...............................  11 
4.1(a) Primary Trial  ................................ ................................ ................................ ...............................  11 
4.1(b) Observational Cohort  ................................ ................................ ................................ .................  11 
4.2.  EXCLUSION CRITERIA  ................................ ................................ ................................ ..............................  11 
4.2(a) Primary Trial  ................................ ................................ ................................ ...............................  11 
4.2(b) Observational Cohort  ................................ ................................ ................................ .................  12 
4.3.  RECRUITMENT AND IDENTIFICATION OF PARTICIPANTS  ................................ ................................ .................  12 
4.4.  VULNERABLE POPULATIONS  ................................ ................................ ................................ .....................  13 
5. STUDY PROCEDURES, EVALUATIONS, AND SCHEDULE  ................................ ................................ ... 13 
5.1 STUDY VISIT PROCEDURES  ................................ ................................ ................................ ........................  13 
5.1.1 Pre -trial ................................ ................................ ................................ ................................ ........  13 
5.1.2. Screening  ................................ ................................ ................................ ................................ .... 13 
5.1.3. Enrol lment  ................................ ................................ ................................ ................................ .. 14 
5.1.4. Visit 1 / Week -0 (baseline)  ................................ ................................ ................................ ..........  14 
5.1.5. Visit 2 / Week -2 (14 days +/ - [ADDRESS_1264207] visit)  ................................ ................................ ... 15 
5.1.6. Visit 3 / Wee k-4 (14 days +/ - [ADDRESS_1264208] visit)  ................................ ................................ ... [ADDRESS_1264209] at week -6 (14 days +/ - [ADDRESS_1264210] visit)  ................................ ...............................  16 
5.1.8. Visit 4 / Week -8 (14 days +/ - [ADDRESS_1264211] injection)  ................................ ...........................  [ADDRESS_1264212] at week -10 (14 days +/ - [ADDRESS_1264213] visit)  ................................ .............................  17 
5.1.10. Visit 5 / Week -12 (14 days +/ - [ADDRESS_1264214] injection)  ................................ .......................  17 
5.1.11. Visit 6 / Week -16 (28 days +/ - [ADDRESS_1264215] visit) ................................ ...............................  [ADDRESS_1264216] at week -20 (28 days +/ - [ADDRESS_1264217] visit)  ................................ ...........................  18 
5.1.13. Visit 7 / Week -24 (primary endpoint; 28 days +/ - [ADDRESS_1264218] 
injection)  ................................ ................................ ................................ ................................ ...............  18 
5.1.14. Visit 8 / Week -36 (84 days +/ - [ADDRESS_1264219] visit) ................................ ...............................  18 
5.2.  EARLY WITHDRAWAL / UNSCHEDULED VISITS ................................ ................................ .............................  19 
Page 6 of 30 5.3.  PARTICIPANT STIPENDS AND PAYMENTS  ................................ ................................ ................................ .... 19 
5.4.  TABLE 1: STUDY SCHEDULE OF EVENTS (PRIMARY TRIAL) ................................ ................................ .............  [ADDRESS_1264220] : IXEKIZUMAB ................................ ................................ ................................ .. 21 
6.2.  DOSING AND ADMINISTRATION  ................................ ................................ ................................ ................  21 
6.3.  STORAGE  ................................ ................................ ................................ ................................ ..............  21 
6.4.  CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ................................ .. 21 
6.4.1. Concomitant Medication Recording  ................................ ................................ ...........................  21 
6.4.2. Prohibited Medications, Treatments, and Procedures  ................................ ...............................  21 
6.4.3. Permitted Medications, Treatments, and Procedures  ................................ ................................  21 
7. STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..... 22 
7.1.  SAMPLE SIZE COMPUTATION AND POWER ANALYSIS  ................................ ................................ ...................  22 
7.2.  STATISTICAL ANALYSIS PLAN ................................ ................................ ................................ ....................  22 
7.2.1. Primary Endpoint Analysis  ................................ ................................ ................................ ..........  22 
7.2.2. Secondary Endpoint Analyses:  ................................ ................................ ................................ .... 22 
7.2.3. Exploratory Endpoint Analyses  ................................ ................................ ................................ ... 23 
8. SAFETY  ................................ ................................ ................................ ................................ .........  23 
8.1.  SPECIFICATION OF SAFETY PARAMETERS  ................................ ................................ ................................ .... 23 
8.2.  DEFINITIONS  ................................ ................................ ................................ ................................ .........  23 
8.2.1. Adverse Event (AE)  ................................ ................................ ................................ ......................  23 
8.2.2. Serious Adverse Event (SAE)  ................................ ................................ ................................ .......  24 
8.2.3. Unantic ipated Problems (UP)  ................................ ................................ ................................ ..... 24 
8.3.  ADVERSE EVENT ASSESSMENT AND FOLLOW -UP ................................ ................................ .........................  24 
8.4.  REPORTING PROCEDURES  ................................ ................................ ................................ ........................  25 
8.4.1. OHSU IRB Reporting of Unanticipated Problems and Adverse Events  ................................ .......  25 
8.4.2. SAE Reporting to the Study Drug Manufacturer  ................................ ................................ ........  25 
8.5.  DATA SAFETY MONITORING PLAN ................................ ................................ ................................ ............  25 
8.6.  POTENTIAL RISKS ................................ ................................ ................................ ................................ ... 26 
8.7.  PARTICIPANT REMOVAL FROM THE TRIAL DUE TO ADVERSE EVENTS  ................................ ...............................  26 
9. DATA HANDLING & MANAGEMENT RESPONSIBILITIES  ................................ ................................ .. 27 
9.1.  PARTICIPANT & DATA CONFIDENTIALITY  ................................ ................................ ................................ .... 27 
9.2.  DATA COLLECTION & STORAGE : PRIVACY , CONFIDENTIALITY & SECURITY  ................................ .......................  [ADDRESS_1264221] (Epic)  ................................ ............................  28 
9.2.5. Photography  ................................ ................................ ................................ ...............................  28 
9.2.6. Tel emedicine Platform  ................................ ................................ ................................ ................  28 
10. ETHICS/PROTECTION OF PARTICIPANTS  ................................ ................................ ......................  [ADDRESS_1264222]  ................................ ................................ ................................ ..............  29 
10.3.  INFORMED CONSENT  ................................ ................................ ................................ ............................  29 
10.4.  CONSENT PROCEDURES AND DOCUMENTATION  ................................ ................................ ........................  29 
10.5.  PROTOCOL REVIEW  ................................ ................................ ................................ ..............................  29 
10.6.  CHANGES TO PROTOCOL  ................................ ................................ ................................ .......................  29 
Page 7 of 30 11. PUBLICATION AND DISSEMINATION POLICY  ................................ ................................ ................  30 
12. REFERENCES  ................................ ................................ ................................ ...............................  30 
 
 
ABBREVIATIONS  
 
AE Adverse Event  
BSA Body Surface Area  
CARD14  CAspase  Recruitment D omain family, member 14  
CBC  Complete Blood Count  
CMP  Comprehensive Metabolic Panel  
CRF Case Report Form  
DLQI  Dermatology Life Quality Index  
EDC  Electronic Data Capture  
HBV Hepatitis B Virus  
HCV  Hepatitis C Virus  
HIV Human Immunodeficiency Virus  
IL17 Interleukin -17 
IND Investigational New Drug  
iPRPASI  Individual PRP Area and Severity Index  
NAPSI  Nail Psoriasis Severity Index  
NRS  Numeric Rating Scale  
OHRP  Office for Human Research Protections  
OHSU  Oregon Health and Science University  
PASI  Psoriasis Area and Severity Index  
PGA  Physician’s Global Assessment  
PI [INVESTIGATOR_312181]’s Global Assessment  
PRP Pi[INVESTIGATOR_312182], O bjective, Assessment, Plan  
Th17  T Helper 17 cell  
UP Unanticipated Problem  
 
 
  
Page 8 of 30 1.  BACKGROUND  
1.1. Overview of Pi[INVESTIGATOR_312183] P ilaris (PRP) and  Ixekizumab   
Pi[INVESTIGATOR_173798] (PRP) is a rare and poorly understood severe inflammatory cutaneous disease 
characterized by [CONTACT_312229] (often full -body) erythematous plaques, skin flaking and ichthyosis, painful  
thickening  and cracking  of the palms and soles , hair loss, crumbling nails, and severe skin pruritus and 
burning. The most common type of PRP affects otherwise -healthy adults and may be explosive in onset. 
Although PRP does not affect internal organs and  no quality -of-life impact studies have been publish ed, 
the high degree of morbidity is perhaps best illustrated by [CONTACT_901347] a 
PRP Facebook support group (with >800 members):   
“All I want is normal skin. .. for my eyes to stop watering constantly, to take off my clothes one time 
and not be shrouded by a cloud of dusty skin flakes ...” 
“My husband can barely walk or use his hands.”  
“My scalp is like the Sahara Desert experiencing the dust storm of the century.”  
“I want my life back!!! Please.”  
Not surprisingly, one study showed over half of patients with PRP reporting depression (1).  
 
While the pathogenesis of PRP is poorly understood, similarities with inflammatory pathways in psoriasis 
have been reported. For example, a recent case report showed overexpression of cytokines in the Th17 
pathway in cutaneous lesions of PRP , including the primary effector cytokines  IL-17A, IL -17F, and IL -22 
(2). Additionally, familial cases of both psoriasis and PRP have been associated with germline gain -of-
function mutations in the caspase recruitment domain family, member 14 (CARD14) gene (3, 4), and 
cutaneous overexpression of CARD14 was observed in cases of sporadic PRP (5). CARD14 
overexpression in vitro  has also been shown to activ ate the Th17 /IL-[ADDRESS_1264223] (6). 
 
There is no FDA -approved therapy for PRP, not a single published systematic therapeutic clinical trial, 
and no established guidelines for measuring disease severity. Commonly prescribed systemic 
medications include acitretin  and methotrexate, but these have treatment failure rates of over 40% (1) 
and can be limited by [CONTACT_901348]. Tumor necrosis factor inhibitors have been used for PRP but have 
even higher failure rates (1), despi[INVESTIGATOR_901331] a therapeutic trial as 
part of “step -therapy.” There are currently 3 published single -case report s of the use of IL -17 inhibitors for 
PRP, all of which reported rapid disease clearance after only 2 -4 weeks in refractory patients who had 
failed many other therapi[INVESTIGATOR_014]  (7-9). Ixekizumab is a humanized IgG4 monoclonal antibody that  that 
selectively binds with the interleukin 17A (IL -17A) cytokine and inhibits its interaction with the IL -[ADDRESS_1264224] s with PRP who are candidates 
for systemic therapy . 
 
2.2. Secondary Objectives  
Use systematic measurement tools to associate  the severity of cutaneous involvement of PRP with 
quality of life measures, before and after therapy with ixekizumab . 
 
2.3. Exploratory Objectives  
Explore the mechanisms by [CONTACT_901349] s inflammatory milieu in PRP ; evaluate 
the use of telemedicine in clinical trials for rare disease.  
 
3. STUDY DESIGN AND ENDPOINTS  
3.1. Study Design Overview  
This will be an investigator -initiated, open -label pi[INVESTIGATOR_14737] [ADDRESS_1264225] injection and at week -24. Blood tests will be performed 
for screening and safety at Screening, week -4 and week -24. The study schedule is outlined  in Section 
5.4., Table 1 . 
 
Up to 15 additional s ubjects with a current or historic diagnosis of PRP who do not meet eligibility criteria 
for the interventional study will be included in a s a separate cohort. These subjects will not receive study 
drug but will be asked to complete quality of life and symptom severity questionnaires, and provide saliva, 
blood, and /or tissue samples for comparison.  
 
 
3.2. Study Endpoints  
3.2.1.  Primary Endpoint  
Mean change  from baseline  PASI  at week -24 after treatment with ixekizumab.  
The Psoriasis Severity Index (PASI) is a well -validated tool for measuring psoriasis, based  on redness, 
thickness, scale, and body surface area  assessed by [CONTACT_093] , with a maximum score of 72 points. 
This is expected to be a useful tool for PRP, since PRP is characterized by [CONTACT_312231] , and is often initially misdiagnosed as severe psoriasis . The mean thickness score is 
expected to be lower in PRP than psoriasis but the mean body surface area (BSA) is expected to be 
higher than psoriasis. Like often used for psoriasis, a minimum PASI score of 10 to re present moderate to 
severe disease will be used as a cutoff for enrollment in the trial.  
 
3.2.2. Secondary Endpoints A ssessed by [CONTACT_10670]  
• Time to improvement by 50% in the PASI score (PASI 50)  
• Mean reduction in body surface area ( BSA) at week -24. BSA is collected as part of  the PASI 
assessment tool.  
• Proportion of subject s achieving a Physician’s Global Assessment  (PGA)  of 0 or 1 at week -24 
Page 10 of 30 • Proportion of subject s achieving a Palmoplantar Physician’s Global Assessment  (PPPGA)  of 0 or 
1 at week -24. Palmoplantar disease will be assessed separately from overall disease since it has 
high morbidity and may respond differently to therapy.  
• Mean percentage improvement in nail involvement measured  by [CONTACT_312232] 
(NAPSI ) at week -24. The Nail Psoriasis Severity Index (NAPSI) (10) will be used for evaluating 
the fingernails and toenails of subjects with PRP. This is expected to be useful tool because nails 
in PRP have many overlappi[INVESTIGATOR_312184], splinter 
hemorrhages, nail oil drop (yellow -brown) discoloration, and nail bed hyperkeratosis, although 
PRP nails are less likely to have onycholysis and red spots in the lunula (11). 
 
3.2.3. Secondary Endpoints  Assessed by [CONTACT_27720]  
• Proportion of subjects  achieving a 4 -point improvement in quality of life measured by [CONTACT_47738] ( DLQI ) at week -24, and mean improvement in DLQI score at 
week -24. The DLQI  (12) is a validated tool for inflammatory skin conditions. It is a 10 -question 
survey, scored 0 – 30 poi nts. For inflammatory skin conditions, a 4 -point change in DLQI score is 
considered clinically important (13). 
• Mean percentage in improvement of itch measured by 0 – 10-point nu meric rating scale  (NRS)  at 
week -24. The Itch NRS is a subject -administered, 11 -point horizontal scale anchored at 0 and 10, 
with 0 representing “no itch” and 10 representing “worst itch imaginable.”  
• Mean percentage in improvement in burning/pain measured  by 0 – 10-point NRS  at week -24. The 
burning/pain NRS is a subject -administered, 11 -point horizontal scale anchored at 0 and 10, with 
0 representing “no burning/pain” and 10 representing “worst burning/pain imaginable.”  
• Mean change from baseline individual PRP Area and Severity Index ( iPRPASI ) at week -[ADDRESS_1264226] self -assessment score of disease 
involvement and severity, based on a previously published similar tool validated fo r psoriasis  (14). 
• Sustained remission at week -36, [ADDRESS_1264227] induced sustained remission of PRP (15), so there is a potential that treatment may “reset” 
the immune response and lead to long -term improvement in the disease, especially in subjects  
without genetic mutations. Subjects  will be treated with ixekizumab as per the FDA -approved 
psoriasis treatm ent guidelines, and therapy will be stopped after the [ADDRESS_1264228] s will 
be monitored at 24 weeks (primary study endpoint) and then at 36 weeks to assess for sustained 
remission versus relapse.  
 
3.2.4. Exploratory/ Mechanistic  Endpoints  
• Treatment  response, as measured by [CONTACT_47736] 50,  stratified by  [CONTACT_207028] o r absence of  germline 
CARD14 mutations . Genetic CARD14 gain -of-function mutations were identified in 3 families with 
familial PRP as well as 12.5% of individuals with sporadic PRP (3). Genetic CARD14 mutations 
will be measured in study subjects and associated with treatment response to ixekizumab.  
Additionally, de -identified samples will be stored  indefinitely  for future analysis of genes 
associated with PRP.  
• Normalization of CARD14 epi[INVESTIGATOR_901332] -24. Despi[INVESTIGATOR_312186]14 mutations, immunohistochemical staining of CARD14 in 6 of 6 
biopsies from sporadic cases of PRP without germline genetic mutations showed increased 
expression of CARD14 in t he keratinocyte spi[INVESTIGATOR_312187] (2). 
CARD14 is thought to act in a synergistic manner with IL -17, activating the transcription factor 
NF-kB. NF -kB activation was shown in vitro  to stimulate IL -36gamma, which may induce an 
amplifying feedback loop from IL -23 to IL -17 and back again (6). Cutaneous biopsies will be 
obtained from subject s before and 24 weeks after treatment with ixekizumab. Inhibition of IL -17 
by [CONTACT_901350]14 expr ession by [CONTACT_327450].  
Page 11 of 30 • Normalization of cutaneous inflammatory cytokines at week -24. Upregulation of Th17 cytokines 
(IL-17A, IL -17F, IL -22) and pro -inflammatory innate cytokines (TNF, IL -6, IL-12, IL -23, IL -1beta) 
compared to normal skin were  observed in  lesional skin from [ADDRESS_1264229] s with PRP (5). In order to 
better understand the inflammatory pathways involved in PRP, a lesional biopsy will be obtained 
from subject s at week -[ADDRESS_1264230] dose of ixekizumab, and again at week -24. A non -
lesional control biopsy will also be obtained at week -0 if non -lesional skin is available . Cutaneous 
inflammatory cytokines will be analyzed and therapeutic response to ixekizumab is expected to 
correlate with normalization of epi[INVESTIGATOR_901333].  De-identified tissue samples will be 
stored indefinitely for inflammatory analysis.   
• Change in serum or plasma cytokine levels at weeks [ADDRESS_1264231] es may be sent to outside 
laboratories within the [LOCATION_002] for analysis.  
• Effects of  telemedicine on  study size and cost . Participation in the study will be given a final 
questionnaire about the ease , and accessibility , cost savings of using telemedicine for research . 
 
4.  STUDY ENROLLMENT AND WITHDRAWAL  
4.1. Inclusion Criteria  
4.1(a) Primary Trial  
• Diagnosis of PRP by [CONTACT_312228].  
• Male subject  age 18 -99. 
• Female subject  age 18 -99; eit her of non -childbearing potential or of childbearing potential 
who test negative for pregnancy and agree to use a reliable method of birth control or remain 
abstinent during the study and for at least [ADDRESS_1264232] dose of ixekizumab.  
• PASI s core of 10 or greater at baseline.  
• Are a candidate for phototherapy and/or systemic therapy.  
• Willingness to travel to OHSU for all study visits, OR living > 30 miles from OHSU and 
willing/able to participate in remote videoconferencing visits with access t o a computer with 
internet capabilities and webcam.  
• Have given written informed consent approved by [CONTACT_312235].  
4.1(b) Observational Cohort  
• Diagnosis of PRP by [CONTACT_312228]  – subjects may be in remission  or on 
current therapy . 
• Male or female age 18 -99. 
• Have given written informed consent approved by [CONTACT_312235].  
 
4.2. Exclusion Criteria  
4.2(a) Primary Trial  
• Known malignancy or lymphoproliferative disease (except treated basal cell skin cancer, 
treated squamous cell skin cancer, or treated cervical carcinoma in situ) for at least 5 years.  
• Active, untreated, acute or chronic infection  (such as untreated tuberculosis) , or 
immunocompromised to an exten t that such that participation in t he study would pose an 
unacceptable risk to the subject . (Treated infections such as latent tuberculosis after 
completion of the appropriate therapy are not excluded.)  
• Positive for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.  
• Previous treatment with any agent that targets interleukins 17 specifically.  
• Systemic treatment or phototherapy for PRP within the past 4 weeks or 5 half -lives prior to 
baseline, whichever is longer. For biologic therapi[INVESTIGATOR_014], the specific washout periods used wi ll 
be: etanercept <28 days; infliximab, adalimumab, or alefacept <60 days; golimumab <90 
Page 12 of 30 days; ustekinumab <8 months; rituximab or efalizumab <12 months.  
• Have a known allergy or hypersensitivity to any biologic therapy that w ould pose an 
unacceptable risk to the subject  if participating in this study.  
• Have a live vaccine within [ADDRESS_1264233] a live vaccine during 
the course of study.  
• Had any major surgery within [ADDRESS_1264234] . 
• Presence of significant uncontrolled cerebrovascular, respi [INVESTIGATOR_696], hepatic, renal, 
gastrointestinal, endocrine, hematologic, neurologic, or neuropsychiatric disorders, or 
abnormal laboratory screening values that, in the opi[INVESTIGATOR_871], pose an 
unacceptable risk to the subject  if participating in the study or of interfering with the 
interpretation of the data.  
• Presence of inflammatory bowel disease  
• Have clinical laboratory test results at screening that are outsi de the normal reference range 
of the population and are considered clinically significant, or have any of the following specific 
abnormalities: Neutrophil count <1500 cells/µL, lymphocyte count <500 cells/µL, platelet 
count <100,000 cells/µL, AST or ALT > 2.5 times the upper limit of normal, hemoglobin <8.5 
g/dL for male subject s and <8.0 g/dL f or female subject s, serum creatinine >2.0 mg/dL.  
• Women who are lactating or breastfeeding.  
• Have any other condition that precludes the subject  from following and completing the 
protocol, in the opi[INVESTIGATOR_871].  
• Are investigator site personnel d irectly affiliated with this study and/or their immediate families 
(spouse, parent, child, or sibling).  
• Are currently enrolled in, or discontinued from a clinical trial involving an investigational 
product or non -approved use of a drug or device within the  last [ADDRESS_1264235] administration of the drug, whichever is longer, or concurrently enrolled 
in any other type of medical research judged not to be scientifically or medically compatible 
with this study.  
4.2(b) O bservational Cohort  
• Have any condition that precludes the subject  from following and completing the protocol, in 
the opi[INVESTIGATOR_871].  
• Are investigator site personnel directly affiliated with this study and/or their immediate families 
(spouse, p arent, child, or sibling).  
• Are currently enrolled in any type of medical research judged not to be scientifically or 
medically compatible with this study.  
 
4.3. Recruitment and Identification of Participants  
The main trial will  recruit subjects with severe PRP , either newly diagnosed or failing other therapi[INVESTIGATOR_901334].  Patients recruited for the observational cohort will be recruited through 
similar means but with less stringent inclusion/exclusio n criteria as above.  A number of recruitment 
strategies will be utilized for this study proven to be effective by [CONTACT_312236].  
• OHSU and community dermatology clinics  
• OHSU OCTRI Cohort Discovery tool to identify patients  with PRP via Epic , and a phone call to 
those patients  
• Publicity on the PRP Support Group Facebook page  
• Publicity through the PRP Alliance patient advocacy organization, including an email to members 
of the PRP Alliance  
• Research Match  
 
Page [ADDRESS_1264236] with the study team, an overview of the trial will be given.  Because of the rarity of 
PRP, subjects may be traveling from distant locations for the study; thus the phone script is intended to 
be somewhat more comprehensive for a subject to determine if they are interested and abl e to 
participate.  If they would like to participate, a  request for information will be signed by [CONTACT_312237]’s healthcare providers to review records pertinent to the diagnosis of PRP. Once the 
study investigator has reviewed the re cords and confirmed that a diagnosis of PRP has been made by a 
qualified healthcare provider,  an appointment for a screening visit will be made. For subjects in whom  the 
screening visit will be completed by [CONTACT_144891], the informed consent form will be e mailed or mailed to 
the subject prior to the screening visit.  
 
5.1.2 . Screening  
(a) Primary Trial  
Subjects  will read the informed consent form and all questions about the study will be answered  by a 
study investigator and research staff . Scree ning questions will be asked and  eligibility will be determined 
by [CONTACT_312238]. Subjects will be asked abo ut vaccine history to ensure that recommended 
vaccines are up to date, and subjects will be reminded that live vaccines  (such as the intranasal influenza 
vaccine or live varicella zoster vaccine (Zostavax))  are not permitted during the study. An investigat or will 
perform an assessment of PASI to calculate  disease  severity. If all other criteria are met, a blood sample 
will be drawn to screen for HBV, HCV, HIV , and tuberculosis,  and to check CBC and CMP.  [COMPANY_003] skin 
testing may be used if blood testing for tuberculosis is unavailable. A pregnancy test will be performed for 
women of childbearing potential.  If subjects have had HBV, HCV, HIV, and tuberculosis testing within 3 
months prior to screening, records of these results will be sufficient and the tests will not be repeated.  
For interested subjects who live > 30 miles from OHSU, t he screening  visit may be performed via secure 
video -conferencing using the OHSU Nexus (Cisco Meeting) app , in which case the stu dy consent will be 
reviewed  during the telemedicine videoconference  and signed via e -consent in REDCap . The blood draw 
will be performed at the lab of the subject’s  choice  and results will be sent  to the investigators.   
Upon confirmation of normal blood te sts as defined in the exclusion criteria, and rece ipt of the signed 
consent form, subject s will be scheduled for enrollment and Visit [ADDRESS_1264237] will be informed 
and referred to her or his primary care physician for assessment . 
For Spanish -speaking subjects, the English -written consent form will be verbally translated with the help 
of a Spanish interpreter. All questions regarding the study will be translated to study staff and answered 
to patient satisfaction. Subjects will then be provided the adapted boilerplate  consent,  “Consent Form – 
Short – Spanish ,” to sign. A copy of both signed consents will be provided to the patient  and uplo aded in 
the patient’s chart . 
 
(b) Observational Cohort  
Subjects will read the informed consent form and all questions about the study  will be answered by a 
study investigator and research staff.  Screening questions will be asked and eligibility will be de termined 
by [CONTACT_312238].   
Page 14 of 30 For interested subjects who live >30 miles from OHSU, the screening visit may be performed via secure 
video -conferencing using the OHSU Nexus (Cisco Meeting) app, in which case the study consent will be 
reviewed durin g the telemedicine videoconference and signed via e -consent in REDCap.  
Upon confirmation receipt of the signed consent form, subjects will be scheduled for enrollment.  
 
5.1.3 . Enrollment  
The inclusion/exclusion criteria will be re -reviewed and subjects ma y proceed with visit 1  on the same day  
if they continue to meet criteria.  
 
5.1.4 . Visit 1 / Week -0 (baseline)  
(a) Primary Trial  
Visit 1 will be performed at OHSU for all subjects.  
• Study personnel  will gather the following information from the subjects  and record the results in 
REDCap : 
▪ Demographics (sex, gender, race, ethnicity)  
▪ Current medications  
▪ Drug allergies  
▪ Use of alcohol, tobacco, and other substances  
▪ PRP medical history  
▪ General medical history  
▪ Family medical history  
▪ Review of Systems   
▪ Height and weight  
▪ Blood pressure  
▪ Pulse  
• Subjects will enter the following information about their disease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
▪ iPRPASI  
• The subject will be clinically examined by [CONTACT_2413] (clinician or research nurse) who will assess 
the following  and record the results in OHSU REDCap : 
▪ Full body skin exam with documentation of PASI, PGA, PPPGA, and NAPSI  
▪ Examination of the oral mucosa  
▪ Heart and lung auscultation  
▪ Palpation of the cervical, axillary, and inguinal lymph nodes  
▪ Presence of peripheral edema  
• Photographs will be taken of each body region  to visually record extent of disease : head, face, 
anterior trunk, posterior trunk, arms, palms, legs, soles  
• Subjects will undergo a punch biopsy  (consisting of three adjacent 3 mm punch biopsies, a total 
surface area equivalent to the size of a 5 mm punch biopsy)  from affected skin , performed by [CONTACT_98225] . One additional 3 mm punch  biopsy will be obtained from non -lesional skin as a control  if 
non-lesional skin is available . For consistency, skin of back will be chosen for biopsy if an affected 
site is available. If back skin is not available, alternate sites in order of preference will include: chest, 
arm, leg. Location of the biopsy will be carefully documented.  
• Blood will be drawn for serum markers  of disease activity  (approximately 2 ml)  
• A saliva sample will be collected for genetic testing  
• The first dose of [ADDRESS_1264238] undergoes teaching for  future  self-administration.  
• Subjects who live > 30 miles from OHSU and plan to complete future visits by [CONTACT_901351] a scale and sphygmomanometer for future vital sign assessments  
Page 15 of 30  
(b) Observational Cohort  
Participants in the observational cohort will be asked to fill out questionnaires  regarding their medical 
history, disease course, and symptom severity at its worst. They will also be asked to provide one or more 
samples, depending on participant preference. The requested samples will include saliva, blood, and 
tissue, and will be coll ected in the same manner as outlined in 5.1.4. (a). Participants may provide only a 
single sample type and are NOT required to provide each.  
• Questionnaires will completed through an OHSU REDCap survey  and include : 
▪ Demographics (sex, gender, race, ethnicity ) 
▪ Current medications  
▪ Drug allergies  
▪ Use of alcohol, tobacco, and other substances  
▪ PRP medical history  
▪ General medical history  
▪ Family medical history  
▪ DLQI  
▪ NRS for itch and pain  
• Subjects electing to provide a saliva sample will be provided a kit for collection to complete either in 
office or remotely via mail  
• Subjects electing to provide a blood sample with have approximately 2 mL of blood drawn for serum 
markers of disease activi ty 
• Subjects electing to provide a tissue sample will  undergo a punch biopsy  (consisting of three adjacent 
3 mm punch biopsies, a total surface area equivalent to the size of a 5 mm punch biopsy)  from 
affected skin , performed by [CONTACT_2413] . One additio nal 3 mm punch biopsy will be obtained from 
non-lesional skin  as a control , if non -lesional skin is available .  For consistency, skin of back will be 
chosen for biopsy if an affected site is available. If back skin is not available, alternate sites in order of 
preference will include: chest, arm, leg , other . Location of the biopsy will be carefully documented.  
This will be the only encounter for the observational cohort. All additional encounters listed pertain solely 
to the Primary Trial (a) group.  
 
5.1.5 . Visit 2 / Week -2 (14 days +/ - [ADDRESS_1264239] visit)  
Visit 2 will be performed at OHSU or optionally by [CONTACT_901352]  >30 miles from OHSU .  
• Study personnel  will gather the following information from the subjects and record the results in 
REDCap:  
▪ Chance in medications since the last visit  
▪ Change in drug allergies sinc e the last visit  
▪ Change in personal or family medical history since the last visit   
▪ Weight (performed by [CONTACT_312242])  
▪ Blood pressure (performed by [CONTACT_312242])  
▪ Pulse (performed by [CONTACT_312242])  
• Subjects will enter the following information about their disease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
▪ iPRPASI  
• The subject will be clinically examined by [CONTACT_2413] (clinician or research nurse , either in -person 
or via telemedicine ) who will assess the following:  
▪ Full body skin exam with documentation of PASI, PGA, and PPPGA  
• The second d ose of [ADDRESS_1264240] with 
observation and teaching from study personnel . 
 
Page 16 of 30 5.1.6 . Visit 3 / Week -4 (14 days +/ - [ADDRESS_1264241] visit)  
Visit 3 will be performed at OHSU or optionally by [CONTACT_312245] 
>30 miles from OHSU.  
• Study personnel  will gather the following information from the subjects and record the results in 
REDCap:  
▪ Chance in medications since the last visit  
▪ Change in drug allergies since the last visit  
▪ Change in personal or family medical history since the last visit   
▪ Weight (performed by [CONTACT_312242])  
▪ Blood pressure (performed by [CONTACT_901353])  
▪ Pulse (performed by [CONTACT_312242])  
• Subjects will enter the following information about their disease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
▪ iPRPASI  
• The subject will be clin ically examined by [CONTACT_2413] (clinician or research nurse , either in -person 
or via telemedicine ) who will assess the following:  
▪ Full body skin exam with documentation of PASI, PGA, and PPPGA  
• Blood will be drawn for monitoring the CBC and CMP (at a local lab of the subject’s choice for remote 
visits , within a window of +/ - 2 days  of the visit date ) 
• The third dose of [ADDRESS_1264242]  at week -6 (14 days +/ - [ADDRESS_1264243] visit)  
All subjects  will be contact[CONTACT_426] a member of the study team by [CONTACT_756], e -mail, text message , or 
videoconference  at 2 weeks ± [ADDRESS_1264244].  
 
5.1.8 . Visit  4 / Week -8 (14 days +/ - [ADDRESS_1264245] injection)  
Visit 4 will be performed at OHSU or  optionally  by [CONTACT_312245] 
>30 miles from OHSU.  
• Study personnel  will gather the following information from the subjects and rec ord the results in 
REDCap:  
▪ Chance in medications since the last visit  
▪ Change in drug allergies since the last visit  
▪ Change in personal or family medical history since the last visit   
▪ Weight (performed by [CONTACT_312242])  
▪ Blood pres sure (performed by [CONTACT_312242])  
▪ Pulse (performed by [CONTACT_312242])  
• Subjects will enter the following information about their disease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
▪ iPRPASI  
• The subject will be clinically examined by [CONTACT_2413] (clinician or research nurse , either in -person 
or via teleme dicine ) who will assess the following:  
▪ Full body skin exam with documentation of PASI, PGA, and PPPGA  
• The fifth dose of [ADDRESS_1264246] at week -10 (14 days +/ - [ADDRESS_1264247] visit)  
All subjects  will be contact[CONTACT_426] a member of the study team by [CONTACT_756], e -mail, text message , or 
videoconference  at 2 weeks ± [ADDRESS_1264248].  
 
5.1.10 . Visit 5 / Week -12 (14 days +/ - [ADDRESS_1264249] injection)  
Visit 5 will be performed at OHSU or optionally by [CONTACT_901354] 
>30 miles from OHSU.  
• Study personnel  will gather the following information from the subjects and record the results in 
REDCap:  
▪ Chance in medications since the last visit  
▪ Change in drug allergies since the last visit  
▪ Change in pers onal or family medical history since the last visit   
▪ Weight (performed by [CONTACT_312242])  
▪ Blood pressure (performed by [CONTACT_312242])  
▪ Pulse (performed by [CONTACT_312242])  
• Subjects will enter the following information about their disease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
▪ iPRPASI  
• The subject will be clinically examined by [CONTACT_2413] (clinician or research nurse , either in -person 
or via telemedicine ) who will assess the following:  
▪ Full body skin exam with documentation of PASI, PGA, and PPPGA  
• The seventh dose of [ADDRESS_1264250] with 
observation and teaching fro m study personnel . 
 
5.1.11 . Visit 6 / Week -16 (28 days +/ - [ADDRESS_1264251] visit)  
Visit 6 will be performed at OHSU or optionally by [CONTACT_312245] 
>30 miles from OHSU.  
• Study personnel  will gather the following information from the subjects and record the results in 
REDCap:  
▪ Chance in medications since the last visit  
▪ Change in drug allergies since the last visit  
▪ Change in personal or family medical history since the last visit   
▪ Weight (performed by [CONTACT_312242])  
▪ Blood pressure (performed by [CONTACT_312242])  
▪ Pulse (performed by [CONTACT_312242])  
• Subjects will enter the following information about their di sease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
▪ iPRPASI  
• The subject will be clinically examined by [CONTACT_2413] (clinician or research nurse , either in -person 
or via telemedicine ) who will assess the following:  
▪ Full body sk in exam with documentation of PASI, PGA, and PPPGA  
• The eight h dose of [ADDRESS_1264252] at week -20 (28 days +/ - [ADDRESS_1264253] visit)  
All subjects  will be contact[CONTACT_426] a member of the study team by [CONTACT_756], e -mail, text message , or 
videoconference  at 2 weeks ± [ADDRESS_1264254].  
 
5.1.13 . Visit 7 / Week -24 (primary endpoint; 28 days +/ - [ADDRESS_1264255] 
injection)  
Visit 7 wi ll be performed at OHSU for all subjects.  
• Study personnel  will gather the following information from the subjects and record the results in 
REDCap:  
▪ Chance in medications since the last visit  
▪ Change in drug allergies since the last visit  
▪ Change in personal or family medical history since the last visit   
▪ Weight  
▪ Blood pressure  
▪ Pulse  
• Subjects will enter the following information about their disease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
▪ iPRPASI  
• The subject will be clinically examined by [CONTACT_2413] (clinician or research nurse) who will assess 
the following:  
▪ Full body skin exam with documentation of PASI, PGA, PPPGA, and NAPSI  
▪ Examination of the oral mucosa  
▪ Heart and lung auscultation  
▪ Palpation of the cervical, axillary, and inguinal lymph nodes  
▪ Presence of peripheral edema  
• Photographs will be taken of each body region: head, face, anterior trunk, posterior trunk, arms, 
palms, legs, soles  
• Blood will be drawn for monitoring t he CBC and CMP, as well as serum markers  of disease activity  
• Subjects will undergo a n endpoint punch biopsy  (consisting of three adjacent 3 mm punch biopsies)  
in the same body region as the first documented biopsy (back, chest, arm, or leg), preferably in an 
area affected by [CONTACT_901355].  
• Subjects will answer questions about their experience will telemedicine and remote visits.  
 
5.1.14 . Visit 8 / Week -36 (84 days +/ - [ADDRESS_1264256] visit)  
Visit 8 will be performed at OHSU or optionally by [CONTACT_901356] 
>30 miles from OHSU.  
• Study personnel  will gather the following information from the subjects and record the results in 
REDCap:  
▪ Chance in medications since the last visit  
▪ Change in drug allergies since the last visit  
▪ Change in personal or family medical  history since the last visit   
▪ Weight (performed by [CONTACT_312242])  
▪ Blood pressure (performed by [CONTACT_312242])  
▪ Pulse (performed by [CONTACT_312242])  
• Visit 8 Subjects will enter the following information about their disease and medical history via OHSU 
REDCap survey : 
▪ DLQI  
▪ NRS for itch and pain  
Page 19 of 30 ▪ iPRPASI  
• The subject will be clinically examined by [CONTACT_2413] (clinician or research nurse , either in -person 
or via telemedicin e) who will assess the following:  
▪ Full body skin exam with documentation of PASI, PGA, and PPPGA  
 
5.2. Early Withdrawal  / Unscheduled Visits  
If the subject  wishes to withdraw from the trial  before week -24, they will be asked to attend for a final trial 
(early termination) visit.  At this visit, if the subject  is willing, the same procedures as for the primary 
outcome / week -[ADDRESS_1264257] withdraws after the week -24 visit, the final week -
36 visit will be carried out ea rly instead.  
 
5.3. Participant Stipends and Payments  
Participants enrolled in the primary trial (a) will be paid $ 50 for all visits that do not involve skin biopsy 
(Screening and visits 2, 3, 4, 5, 6, 8) and $150 for the two visits that involve skin biopsy  (baseline and visit 
7), for a total of $650. Other contacts are not reimbursed. For those subjects traveling >200 miles to 
OHSU, travel will be reimbursed at the federal Internal Revenue Service  suggested rate of $0.535/mile up 
to 1000 miles (range $214 - $1070 for a round -trip visit to OHSU) for each of the two in -person visits 
(baseline and visit 7).  
 
Participants enrolled in the observational cohort (b) will not be eligible for reimbursement.  
 
  
Page 20 of 30 5.4. Table 1: Study Schedule  of Events  (Primary Trial)  
Visit  Pre-
trial Screening*  Enrollment  V1 V2 V3 - V4 - V5 V6 - V7 V8 
Week  WK
0 WK
2* WK
4* WK
6 WK
8* WK
10 WK
12* WK
16* WK
20 WK
24 WK
36* 
Baseline Documentation  
Informed consent   X             
Confirmation of dx  X              
Investigator 
assessment   X  X X X  X  X X  X X 
Medical history   X  X           
Exclusion/Inclusion 
criteria   X X            
Dosing  
Injection 
counseling/training     X           
Injection review      X X X X X X X X   
Study drug 
dispensing     X           
Study drug 
injection/dose**     X X X X X X X X X   
Laboratory Studies  
Blood draw***   X  X  X       X  
Other Assessments  and Procedures  
Skin biopsy     X         X  
Adverse events     X X X X X X X X X X X 
Subject REDCap 
survey     X X X  X  X X  X X 
Phone contact  X      X  X   X   
 
*Visit optionally to be performed via secure telemedicine videoconferencing for subjects >30 miles from Oregon 
Health & Science University.  
**Ixekizumab subcutaneous dose: 160mg on W0, 80mg on all subsequent dosing time points (W2, W4, W6, W8, 
W10, W12, W 16, and W20).  
***Laboratory studies  will include: HBV, HCV, HIV, tuberculosis, CBC, CMP , pregnancy testing for women who may 
be able to become pregnant, and markers of disease activity.  
 
  
Page [ADDRESS_1264258]: Ixekizumab  
Ixekizumab is a humanized monoclonal antibody that binds and blocks IL -17.  
 
6.2. Dosing and Administration  
Ixekizumab treatment will be administered at the FDA -approved dosing schedule for psoriasis  as follows : 
• 160 mg SC injection at week -0 
• [ADDRESS_1264259] be recorded. Subjects will be asked about 
concomitant medic ations at each study visit.  
 
6.4.2 . Prohibited Medications, Treatments, and Procedures  
The following therapi[INVESTIGATOR_901335]:  
• Treatment with systemic therapy  intended to treat PRP  within the washout period specified in  the 
exclusion criteria , including prednisone, methotrexate, cyclosporine, acitretin, and injectable 
biologic therapi[INVESTIGATOR_014]. These medications could have a negative safety impact on the subject s 
enrolled and  confound the results of the study.  
• Live vaccines  
• Phototherapy  within the 4 -week washout period  
 
6.4.3 . Permitted Medications, Treatments, and Procedures  
The following medications will be permitted during the course of the study:  
• Topi[INVESTIGATOR_901336]  
• Non-live vaccines (such as the non -live annual influenza vaccine, non -live herpes zoster vaccine 
(Shingrix), rabies , or tetanus) and/or emergency vaccines are allowed  
• Acetaminophen, aspi[INVESTIGATOR_248], or ibuprofen as needed  
• Subject s will maintain their usual medication regimen for other concomitant diseases throughout 
the study unless specifically excluded in the protocol. Subject s taking concomitant medications 
should be on a stable dose throughout the study, unless changes need to be made for an AE or 
for appropriate medical management. Additional systemic drugs are to be avoided during the 
study, unless required to treat an AE. Other medications may be allowed, if approved by [CONTACT_1275]. Any changes in medications should be disc ussed with the investigator. Subject s 
Page 22 of 30 should be instructed to consult the investigator or other appropriate study personnel at the site 
before taking any new medications or supplements.  
7. STATISTIC AL CONSIDERATIONS  
7.1. Sample Size Computation and Power Analysis  
This is a pi[INVESTIGATOR_312194]; thus a power analysis was performed with the 
following rough assumptions. With measurement of the mean paired difference in PASI score before 
and after treatment of a minimum of [ADDRESS_1264260] 80% power at the 0.[ADDRESS_1264261]-visit. 
 
7.2.1 . Primary Endpoint Analysis  
• Mean improvement from baseline PASI at week -24 will be analyzed for statistical significance 
using a paired, two -tailed student’s t -test. 
 
7.2.2 . Secondary Endpoint Analyses:  
• Time (weeks) to improvement by 50% in the PASI score (PASI 50) will be reported as  a mean 
with standard deviation and also represented graphically.  
• Mean improvement from baseline BSA at week -24 will be analyzed for statistical significance 
using a paired, two -tailed student’s t -test. 
• The proportion of subject s achieving a Physician’s Global Assessment of 0 or 1 at week -24 will 
be reported as a proportion, and compared with historical estimates of treatment success with 
acitretin and methotrexate (1). 
• The proportion of subject s achieving a Palmoplantar P hysician’s Global Assessment of 0 or 1 at 
week -24 will be reported as a proportion.  
• The mean improvement in nail involvement measured by [CONTACT_312247] (see below) at week -24 will be 
analyzed for statistical significance using a paired, two -tailed student’s t -test. 
• The proportion of subject s achieving a 4 -point improvement in quality of life measu red by [CONTACT_901357] -24 will be reported as a proportion. The mean improvement in DLQI score from week -0 to 
week -24 will be analyzed using a paired, two -tailed student’s t -test. 

Page 23 of 30 • The mean improvement in itch measured by 0 – 10-point subject -reported subjective numeric 
rating scale at week -24 will be analyzed for statistical significance using a paired, two -tailed 
student’s t -test. 
• The mean improvement in burning/pain measured by 0 – 10-point subject -reported subjective 
numeric rating scale at week -24 will be analyzed for statistical significance using a paired, two -
tailed student’s t -test. 
 
7.2.3 . Exploratory Endpoint Analyses  
• Sustained remission at week -36, measured by [CONTACT_312248] -24 to 
week -36, will be analyzed for statistical significance using a paired, two -tailed student’s t -test. 
• Treatment response, as measured by [CONTACT_47736] 50, will be stratified by [INVESTIGATOR_266612]14 germline mutations. 
The proportion of sub jects with a PASI 50 response with and without CARD14 mutations will be 
reported and compared for statistical significance using an unpaired, two -tailed student’s t -test. 
• Epi[INVESTIGATOR_312195]14 will be assessed qualitatively by a trained dermatopa thologist 
who is blinded to the biopsy collection time (before or after therapy).  
• The concentration of 18 different cutaneous cytokines within the tissue biopsy, before and 24 
weeks after treatment, will be analyzed for statistical significance using a par ed, two -tailed 
student’s t -test and also compared with normal skin using a two -tailed, two -sample student’s t -
test with unequal variance.  
 
8. SAFETY  
8.1. Specification of Safety Parameters  
The PI [INVESTIGATOR_901337]. Safety 
assessments will be based on medical review of adverse events and the results of safety evaluations at 
specified time points as described in Section 5.1 Study Visit Procedures.  Any clinically significant adverse 
events persisting at the end of treatment visit will be followed by [CONTACT_901358]/stabilization or death, whichever comes first.  
 
8.2. Definitions  
8.2.1 . Adverse Event (AE)  
An adverse  event is defined as any undesirable physical, psychological or behavioral effect experienced 
by a participant during their participation in an investigational study, in conjunction with the use of the 
investigational product, whether or not considered int ervention -related. In general, this includes signs or 
symptoms experienced by [CONTACT_901359].   
 
AEs may include, but are not limited to:  
• Subjective or objective symptoms spontaneous ly offered by [CONTACT_4538]/or observed by 
[CONTACT_204418].  
• Clinically significant laboratory abnormalities.  
• A significant worsening of the participant’s condition from study entry.  
• Disease signs and symptoms and/or laboratory ab normalities existing prior to the use of the study 
treatment that resolve but then recur after treatment.  
• Disease signs and symptoms and/or laboratory abnormalities existing prior to the use of the study 
treatment which increase in frequency, intensity, o r a change in quality after treatment.  
 
Page 24 of 30 8.2.2 . Serious Adverse Event (SAE)  
An AE or suspected adverse reaction is considered "serious" if, in the view of either the Investigator, it 
results in any of the following outcomes:  
• Death,  
• A life -threatening adverse event,  
• In-patient hospi[INVESTIGATOR_1081],  
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions, or  
• A congenital anomaly/birth defect.  
 
Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_34502], based upon appropriate medical judgment, they may jeopardize the 
participant and/or participant m ay require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include:  
• Allergic bronchospasm requiring intensive treatment in an emergency room or at home,  
• Blood dyscrasias or convulsi ons that do not result in in -patient hospi[INVESTIGATOR_059], or  
• The development of drug dependency or drug abuse.  
 
8.2.3 . Unanticipated Problems (UP)  
The Office for Human Research Protections  (OHRP) considers UPs involving risks to participants or 
others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and 
informed consent document; and (b) the characteristics of the participant population being 
studied;  
• Related or possibly related to participation  in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_9156]); and  
• Suggests that the research places participants or others at a great er risk of harm (including 
physical, psychological, economic, or social harm) than previously known or recognized.  
This study will use the OHRP definition of UP.  
 
8.3. Adverse Event Assessment and Follow -Up 
The occurrence of an UP, AE or SAE may come to the attention of study personnel during study visits 
and interviews of a study parti cipant presenting for medical care, or upon review by [CONTACT_978] . All AEs 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate CRF. Information to be collected includes event description, time of onset, c linician’s 
assessment of severity, seriousness, expectedness, relationship to study product (assessed only by 
[CONTACT_8703] a diagnosis), and date of resolution/stabilization of the event. 
All AEs occurring while on study mu st be documented appropriately regardless of relationship. All AEs 
will be followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. Howeve r, if the study participant’s condition deteriorates at any time 
during the study, it will be recorded as an AE.  
 
Page 25 of 30 Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be perfo rmed. AEs characterized as intermittent require documentation of 
onset and duration of each epi[INVESTIGATOR_1865].  
 
At each study visit, the Investigator will inquire about the occurrence of AE/SAEs since the last visit. 
Events will be followed for outcome information u ntil resolution or stabilization.  
 
The Investigator will record all reportable events with start dates occurring any time after informed 
consent is obtained until the week -[ADDRESS_1264262] be reported by [CONTACT_901360]: Prompt Reporting Requirements (HRP -801). At a minimum, events requiring reporting to the 
IRB include:  
• Any new or increased risk related to the research, including AEs or IND safety reports that require 
a change to the protocol or consent,  
• New FDA black box warning,  
• Publications identifying new risks,  
• Data Safety Monitoring Board/Committee lette rs recommending changes or discussing new risks  
• Unauthorized disclosure of confidential participant information  
 
8.4.2. SAE Reporting to the Study Drug Manufacturer  
SAEs will also be reported to Lilly’s Global Patient Safety via fax within [ADDRESS_1264263] throughout the study. Concomitant medications will be 
recorded at every study visit. Vital signs including blood pressure and pulse (measured a minimum of 5 
minutes after resting), and weight/BMI will be recorded  at every study visit. Laboratory testing will be 
performed at the screening visit, visit 3 (week -4), and visit 7 (week -24) at a minimum . This will include 
screening for HIV, HVB, HCV , and tuberculosis  as detailed in the exclusion criteria. Baseline, week -4 and 
week -24 laboratory testing will include complete blood counts with differential and a comprehensive 
metabolic panel.  In the event of abnormal laboratory values, additional and/or repeat laboratory testing 
may be requested at the discretion of the stu dy investigator to ensure patient safety.  
 
Subjects will be encouraged to report any potential problems at any time to qualified research staff or PI. 
The occurrence of adverse events will be assessed at each study visit and details including diagnosis, 
severity, possibility of relationship to the study medication (ixekizumab), and action taken will be recorded 
on the AE log in REDCap .  
 
Data s afety monitoring will involve real -time review of adverse events (AE), dropouts, complaints or 
breaches of confidentiality. The review of AEs will be performe d by [CONTACT_978] ( [CONTACT_312264] ) in real time, with 
Page [ADDRESS_1264264] s with psoriasis  are outlined below . The full package insert is publicly available.  
• Ixekizumab is a fully humanized monoclonal antibody. Serious allergic reaction s, including 
angioedema and urticaria  occurred  at a rate of 0.1%  in the ixekizumab clinical trials. Anaphylaxis 
has been reported in post -marketing use.  
• Injection site reactions  including pain, erythema, bruising, and inflammation  occurred in 17% of 
subjec ts who used ixekizumab (versus 3% of the placebo  group ). 
• Ixekizumab may increase the risk of infection. In clinical trials, use of ixekizumab was associated 
with a higher rate of infection than the placebo group (27% versus 23%) , with specifically higher 
rates of u pper respi[INVESTIGATOR_18073], oral candidiasis (thrush), conjunctivitis, and tinea infections.  
• Nausea occurred in 2% of subjects using ixekizumab versus <1% of  the placebo  group.  
• Neutropenia occurred in 11% of subjects treated with ixekizumab (vers us 3% of placebo). The 
severity was considered grade three (<1,000 cells/mm 3) in 0.2% of subjects.  
• Thrombocytopenia occurred in 3% of subjects treated with ixekizumab  (versus 1% of placebo) but 
98% of these were grade 1 (>75,000 cells/mm 3) and were not ass ociated with an increased rate 
of bleeding.  
• New cases of inflammatory bowel disease or exacerbations occurred in 0.3% of subjects treated 
with ixekizumab (versus zero in the placebo  group ). 
The risk to the fetu s or infant in pregnant or lactating women is unknown and this is an exclusion criterion 
from the study. Women who may become pregnant are asked to use a reliable form of birth control. There 
have been no reports to date of harm and no negative effects in laboratory animals. There may be 
additional drug side effects that are not yet known.  
 
Risks of blood draw include discomfort, and a small chance of bleeding,  bruising,  infection , or fainting . 
 
Risks of biopsy include allergic reaction to the local anesthetic (1 in 10,000 risk), infection, bleeding, and 
scar.  
 
Risks of genetic testing include the loss of confidentiality that may affect the subject’s ability to obtain life 
insurance, disability in surance, or long -term care insurance. Even though there are certain genetic 
discrimination and confidentiality protections in both Oregon law and federal law, there is still a small 
chance that the subject  could be harmed if a release occurred.  
 
Although m edical information and medical photographs will be encoded and carefully protected, there is a 
small risk of loss of confidentiality and release of personal information.  
 
8.7. Participant Removal from the Trial due to Adverse Events  
Any participant who exp eriences an adverse event may be withdrawn from the trial at the discretion of the 
Investigator and/or the subject’s  request.  
Page [ADDRESS_1264265] suffers any injury and/or damage from this research project through the fault of the Oregon 
Health & Science Univer sity, its officers or employees, they will have the right to bring legal action against 
the University to recover the damage done subject to the limitation and conditions of the Oregon Tort 
Claims Act.  
 
9. DATA HANDLING & MANAGEMENT  RESPONSIBILITIES  
9.1. Participant & Data Confidentiality  
The information obtained during the conduct of this clinical study is confidential, and unless otherwise 
noted, disclosure to third parties is prohibited . Information contained within this study wil l be maintained in 
accordance with applicable laws protecting participant privacy, including the provisions of the Health 
Insurance Portability and Accountability Act (HIPAA).  
Participant confidentiality is strictly held in trust by [CONTACT_901361](s) and study team. This 
confidentiality is extended to cover testing of biolo gical samples in addition to the clinical information 
relating to participants. Biological samples may be sent to outside laboratories within the [LOCATION_002] for 
analysi s, samples will remain de -identified. T he study protocol, documentation, data, and all other 
information generated will be held in strict confidence.  
Representatives of the IRB or manufacturer supplying study product may inspect all documents and 
records required to be maintained by [CONTACT_737], including but not limited to, medical records (office, 
clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit 
access to such records.  
Upon enrollment,  participants will be assigned a code that will be used instead of their name, medical 
record number or other personally identifying information. Electronic files for data analysis will contain 
only the participant code. Codes will not contain any part of the 18 HIPAA identifiers (e.g., initials, DOB, 
MRN). The key associating the codes and the participants’ personally identifying information will be 
restricted to the Investigator and study staff. The key will be kept secure on a  restricted OHSU network 
drive in a limited access folder.  
The study participant’s contact [CONTACT_21225]. At the end of the study, all records will continue to be kept in a secure location for as 
long a per iod as dictated by [CONTACT_38079].  
 
9.2. Data Collection & Storage: Privacy, Confidentiality & 
Security  
9.2.[ADDRESS_1264266] institutional practices will be followed as described in the 
OHSU’s Information Security Directives  to maintain the confidentiality and security of data collected in this 
study. Study staff will be trained with regard to these procedures.  
9.2.2 . Data Confidentiality  
Loss of participant confidentiality is a risk of participation. Efforts will be made to keep study participant 
identities confidential except as required by [CONTACT_2371]. Participants’ samples will be identified by [CONTACT_233780].  
Specifically, each consenting participant will be assigned a unique coded identifier consisting of numbers. 
This identifier will be associated with the participant throughout the duration of their participation in the 
trial. The coded identifier will also  be used to identify any participant specific samples.  
 
Page 28 of 30 9.2.3 . Data Storage  
Basic accrual tracking information (demographic, consent, visit information) will be captured in OHSU’s 
electronic clinical information research system (eCRIS), hosted on OHSU secu re servers and managed 
by [CONTACT_54830]’s information technology group at their data center in downtown Portland, Oregon. Any 
additional printed documents containing participant identifiers, such as those from the medical record to 
confirm eligibility, will be file d in binders and kept in a locked, secure location.  
Study outcome data will be captured in electronic case report forms (eCRFs) using an electronic data 
capture (EDC) system (REDCap) on OHSU secure servers, which facilitates information being stored in a 
unified format and location. To further preserve confidentiality, PHI in the EDC system will be limited to 
birth date and visit dates , city of residence , and email address – for distribution of REDCap  surveys . The 
REDCap  system is password protected and enc rypted with role -based security, and administered by 
[CONTACT_901362]. All users of the database are assigned a unique ID, username, 
and password and must complete training appropriate to their role before they are authorized to ent er, 
access, and store data in the database.  
Data from correlative studies will be entered into the EDC system by [CONTACT_127896]. All other 
electronic data extracts will be stored only on OHSU computers and restricted drives, limited only to study  
investigators and staff with authorization to access the data.  
Individual participant medical information obtained as a result of this study is considered confidential and 
disclosure to third parties is prohibited. Research materials obtained specifically  for the purposes of this 
study will include biopsies for mechanistic studies and blood tests for CBC, CMP,  HIV, HBV, HCV,  
tuberculosis,  and CARD14 genetic testing. All samples used for mechanistic testing will be coded and 
blinded to the investigator. Dat a regarding medical history and symptom questionnaires will be obtained 
during the course of this study. Absolute confidentiality will be maintained. Only the principal investigator 
[INVESTIGATOR_901338]. All data not stored in REDCap are stored in locked compartments and are 
not released without consent of the participants. If data are used in scientific presentations or 
publications, individual s are never identified. Medical information gathered during the course of the study 
may be given to the participant’s medical team and all appropriate medical personnel responsible for the 
participant’s welfare.  
 
9.2.[ADDRESS_1264267] (Epic)  
An Epic research encounter will be created for each in-person visit. A brief S.O.A.P. note that includes 
study drug administration will be entered into Epic to facilitate communication with the subject’s other 
healthcare providers.  Additionally, all s erious adverse events will be recorded as a brief note in Epic.  
 
9.2.[ADDRESS_1264268]’s study number  and visit number , and kept on the cloud file storage solution provided by [CONTACT_312256].com.  
For purposes of publication or education  (i.e., viewing by [CONTACT_312257]) , any 
identifying features such as the eyes , jewelry,  or a tattoo will be digitally blocked out o f the photo.  
 
9.2.6 . Telemedicine Platform  
The study will use a HIPAA -compliant videoconferencing platform ( Nexus/Cisco Meeting) . A one -time-use 
unique hyper link will be sent to the study subject for each visit, via OHSU MyChart  or email . No protected 
health information will be stored unless it is deliberately captured and downloaded by [CONTACT_312258]. For convenience, w e will choose a platform that works 
natively within a browser with the use of static plugins and that allows patients to access the study “room” 
via a specific URL without need for preregistration . The platform will use standard audio/video capabilities 
and will allow access through mobile devices.      
Page 29 of 30  
10. ETHICS/PROTECTION OF PARTICIPANTS  
10.1. Ethical Standard  
The Investigator will ensure that this study is  conducted in adherence with the protocol and International 
Conference on Harm onization Good Clinical Practice E6 (ICH -GCP).  
 
10.2. Institutional Review Board  
The pr otocol, informed consent form , recruitment materials, and all participant materials will be submitted 
to the IRB for review and approval. Approval of both the protocol and the consent  form must be obtained 
before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_118694]. All changes to the consent form will be IRB 
approved; a determination will  be made regarding whether previously consented participants need to be 
re-consented.  
 
10.3. Informed Consent  
Written informed consent will be obtained from all participants, or the legally authorized representa tive of 
the participant, participating in this trial, as stated in the Informed Consent  section of 21 CFR Part 50 . If a 
participant’s signature [CONTACT_901366], and for all participants under the age of 18, the Investigator 
must ensure that the informed consent is signed by [CONTACT_2299]’s legally authorized representative. 
Documentation of the consent process and a copy of the signed consent shall be main tained in the 
participant’s medical record.  
 
10.4. Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreement to participate in the study 
and continues throughout the individual’s study participation. Extensive discussion of risks and possible 
benefits of participation will be provided to the participants and their families as appropriate. Consent 
forms will be IRB -approved and the participant w ill be asked to read and review the document. The 
Investigator will explain the research study to the participant and answer any questions that may arise. All 
participants will receive a verbal explanation in terms suited to their comprehension of the purp oses, 
procedures, and potential risks/benefits of the study, alternatives to participation, and of their rights as 
research participants. Participants will have the opportunity to carefully review the written consent form 
and ask questions prior to signing . The participants should have the opportunity to discuss the study with 
their surrogates or think about it prior to agreeing to participate. The participant will sign the informed 
consent document prior to any procedures being done specifically for the st udy. The participants may 
withdraw consent at any time throughout the course of the trial. A copy of the informed consent document 
will be given to the participants for their records. The rights and welfare of the participants will be 
protected by [CONTACT_901363].  Consent  and reconsent  of Spanish -speaking subjects will be 
obtained through the help of an interpreter as detailed above in sect ion 5.1.2.  
 
10.5. Protocol Review  
The protocol and informed consent form for this study must be reviewed and approved in writing by [CONTACT_901364].   
 
10.6. Changes to Protocol  
Any modification of this protocol must be do cumented in the form of a protocol revision or amendment 
submitted by [CONTACT_16270], before the revision or amendment may be 
implemented.  The only circumstance in which the amendment may be initiated without regulatory 
Page [ADDRESS_1264269] notify the IRB within 5 business days after the implementation.  
 
11. PUBLICATION AND DISSEMINATION POLICY  
The study resu lts will be published in a peer -reviewed journal.  Participants will not be identified in any 
publications.  
This protocol will be registered in the ClinicalTrials.gov website. This registration will occur after IRB 
approval.  
 
12. REFERENCES  
1. N. A. Ross  et al. , Epi[INVESTIGATOR_50123], Clinicopathologic, Diagnostic, and Management Challenges of 
Pi[INVESTIGATOR_312213]: A Case Series of 100 Patients. JAMA dermatology  152, 670 -675 
(2016).  
2. L. Feldmeyer  et al. , Interleukin 23 -Helper T Cell 17 Axis as a Treatment Target for Pi[INVESTIGATOR_901339]. JAMA dermatology ,  (2017).  
3. D. Fuchs -Telem  et al. , Familial pi[INVESTIGATOR_901340]14. 
American journal of human genetics  91, 163 -170 (2012).  
4. C. T. Jordan  et al. , PSORS2 is due to mutations in CARD14. American journal of human 
genetics  90, 784 -795 (2012).  
5. O. Eytan  et al. , Increased epi[INVESTIGATOR_901341]14 in a 
series of patients with sporadic pi[INVESTIGATOR_173798]. The British journal of dermatology  170, 
1196 -1198 (2014).  
6. M. A. Lowes, C. B. Russell, D. A. Martin, J. E. Towne, J. G. Krueger, The IL -23/T17 pathogenic 
axis in psoriasis is amplified by [CONTACT_901365]. Trends in immunology  34, 174 -181 
(2013).  
7. M. L. Gauci  et al. , Successful treatment of type II pi[INVESTIGATOR_901342]. 
JAAD case reports  2, 462 -464 (2016).  
8. D. Schuster, A. Pfister -Wartha, L. Bruckner -Tuderman, C. M. Schempp, Successful Treatment 
of Refractory Pi[INVESTIGATOR_901343]. JAMA dermatology  152, 1278 -1280 
(2016).  
9. I. Kevric, J. Slazevich, Response of persistent juvenile pi[INVESTIGATOR_901344]. 
Journal of the American Academy of Dermatology  75(5)(Suppl. 1) , AB268 (2016).  
10. P. Rich, R. K. Scher, Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. 
Journal of the American Academy of Dermatology  49, 206 -212 (2003).  
11. T. S. Sonnex, R. P. Dawber, C. B. Zachary, P. R. Millard, A. D. Griffiths, The n ails in adult type 
1 pi[INVESTIGATOR_173798]. A comparison with Sezary syndrome and psoriasis. Journal of the 
American Academy of Dermatology  15, 956 -960 (1986).  
12. A. Y. Finlay, G. K. Khan, Dermatology Life Quality Index (DLQI) --a simple practical measu re for 
routine clinical use. Clinical and experimental dermatology  19, 210 -216 (1994).  
13. M. K. Basra, R. Fenech, R. M. Gatt, M. S. Salek, A. Y. Finlay, The Dermatology Life Quality 
Index 1994 -2007: a comprehensive review of validation data and clinical r esults. The British 
journal of dermatology  159, 997 -1035 (2008).  
14. L. Chularojanamontri, C. E. Griffiths, R. J. Chalmers, The Simplified Psoriasis Index (SPI): a 
practical tool for assessing psoriasis. The Journal of investigative dermatology  133, 1956 -1962 
(2013).  
15. R. Ruiz Villaverde, D. Sanchez Cano, Successful treatment of type 1 pi[INVESTIGATOR_901345]. European journal of dermatology : EJD  20, 630 -631 (2010).  
  
 